Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€546.80

€546.80

0.040%
0.2
0.040%
€568.09
 
20.05.24 / Tradegate WKN: 857209 / Symbol: TMO / Name: Thermo Fisher / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Thermo Fisher Scientific Inc. Stock

With only a change of €0.20 (0.040%) the Thermo Fisher Scientific Inc. price is nearly unchanged from yesterday.
The stock is an absolute favorite of our community with 26 Buy predictions and no Sell predictions.
With a target price of 568 € there is a slightly positive potential of 3.88% for Thermo Fisher Scientific Inc. compared to the current price of 546.8 €.
So far the community has only identified positive things for Thermo Fisher Scientific Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Thermo Fisher Scientific Inc. in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Thermo Fisher Scientific Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Thermo Fisher Scientific Inc. 0.040% -0.110% 6.922% 12.026% 13.444% 43.668% 132.879%
QuidelOrtho Corp. -0.510% -3.465% 5.978% -50.869% -42.495% -60.414% -
Boston Scientific 0.720% 2.963% 9.449% 40.008% 35.109% 102.683% 110.224%
Waters Corp. -0.030% 1.143% 18.452% 32.016% 8.411% 27.891% 75.814%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-04

Upon examining the submitted financials of Thermo Fisher Scientific Inc., symbol TMO, the initial impression is that the company stands robust in its fiscal health. A key point that stands out from the balance sheets of the last three years is the consistent growth in total assets, suggesting an expanding business operation. Moreover, the ability of the company to generate significant net income, as seen from the income statements, reveals strong company profitability and operational efficiency. As for the cash flow statements, they reflect a company that efficiently converts its earnings into cash, which is critical for maintaining liquidity and funding operations.

** - Rising Total Assets: In the past three years, total assets of TMO have shown an upward trajectory, from $69.05 billion in 2020 to nearly $97.29 billion by the end of 2022. Such an increase indicates strategic acquisitions or growth in the company's operations. - Decreasing Debt-to-Equity Ratio: The total liabilities in comparison to the stockholder equity have decreased from 2020's parity level to a more prudent ratio in 2022. This suggests an improved financial stability and lowered financial risk. - Stable Cash Position: TMO's cash reserves are healthy, with a significant jump between 2020 and 2022, from $10.33 billion to $8.52 billion, which is essential for buffering against market volatility or unexpected expenses. - Strong Net Income Performance: The company's ability to generate profit is evident, with net income showing a consistent rise—from $6.38 billion in 2020 to $6.95 billion in 2022. - Solid Return on Equity (ROE): The Return on Equity has been impressive, highlighting the company’s ability to generate income from the investment of its shareholders, with an ROE of 0.1328. - Appreciable Free Cash Flow: Free cash flow figures are impressive, signifying the firm's ability to generate cash after funding the expansion of their asset base, with a free cash flow of $6.91 billion in 2022.

** - Growing Intangibles and Goodwill: The balance sheet shows a large proportion of intangible assets and goodwill, which can be a cause for concern as these values are susceptible to write-downs if acquisitions do not perform as expected. - Net Tangible Assets in the Negative: The negative net tangible assets figure indicates that the company's valuation heavily relies on intangible assets, which could result in volatility if the intrinsic value of these intangibles changes significantly. - Higher Composition of Long-term Debt: An increase in long-term debt from about $19.11 billion in 2020 to $28.91 billion in 2022 may signal aggressive financing that could pose risks if not managed properly. - Declining Revenue Growth: The revenue has seen a slight decline year-over-year, which might be a point of concern for growth trajectory expectations.

Comments

Prediction Buy
Perf. (%) 2.00%
Target price 627.120
Change
Ends at 30.04.25

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target raised by analysts at HSBC Holdings plc from $660.00 to $670.00. They now have a "buy" rating on the stock.
Ratings data for TMO provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 2.45%
Target price 568.093
Change
Ends at 25.04.25

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $600.00 to $610.00. They now have a "buy" rating on the stock.
Ratings data for TMO provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 2.21%
Target price 608.465
Change
Ends at 25.04.25

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target raised by analysts at JPMorgan Chase & Co. from $600.00 to $650.00. They now have an "overweight" rating on the stock.
Ratings data for TMO provided by MarketBeat
Show more